Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.36 |
| ▸ | LIPE | Q05469 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16650986 | 0.83 | IDO1 (0.40) | IDO1PDE4BUSP30GPR119LIPE | |
| SCHEMBL16662458 | 0.78 | USP30 (0.41) | USP30GPR119NAMPTAOC3NR1H2 | |
| SCHEMBL20164090 | 0.77 | DPP4 (0.45) | IDO1PDE4BDPP4USP30GPR119 | |
| SCHEMBL20164106 | 0.75 | DPP4 (0.42) | IDO1PDE4BDPP4USP30GPR119 | |
| SCHEMBL19734488 | 0.75 | DPP4 (0.42) | IDO1PDE4BDPP4USP30GPR119 | |
| SCHEMBL23211978 | 0.75 | HDAC1 (0.46) | IDO1PDE4BDPP4USP30GPR119 | |
| SCHEMBL19734489 | 0.75 | DPP4 (0.42) | IDO1PDE4BDPP4USP30GPR119 | |
| SCHEMBL21384664 | 0.75 | HDAC1 (0.46) | IDO1PDE4BDPP4USP30GPR119 | |
| SCHEMBL25199634 | 0.75 | RORC (0.48) | IDO1USP30GPR119NAMPT | |
| SCHEMBL3032608 | 0.75 | NPC1 (0.43) | IDO1PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624225-B2 | Quinolinyl modulators of RORγt | JANSSEN PHARMACEUTICA NV (BE) | 2017-04-18 | — | — | US | disclosed |
| US-20150111870-A1 | QUINOLINYL MODULATORS OF RORyt | JOHNSON & JOHNSON (US) | 2015-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150111870-A1 | QUINOLINYL MODULATORS OF RORyt | RORC, RORA, RORB | IDO1 456/4885PDE4B 742/4885DPP4 3721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.